Status:
COMPLETED
Effects of Schema Therapy vs. Cognitive Behavioral Therapy vs. Individual Supportive Therapy
Lead Sponsor:
Max-Planck-Institute of Psychiatry
Collaborating Sponsors:
Ludwig-Maximilians - University of Munich
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The OPTIMA-Study: Optimized Treatment Identification at the Max Planck Institute of Psychiatry: An outline Depressive disorders represent one of the most frequent diseases worldwide. Schema therapy, ...
Eligibility Criteria
Inclusion
- Main diagnosis of major depressive disorder, single episode or recurrent, moderate or severe without psychotic symptoms according to DSM-5 criteria (F32.1, F32.2, F33.1, F33.2 according to ICD-10)
- age between 18 and 75 years
- informed consent to the study procedures and assessments (in written form)
Exclusion
- Major depressive disorder, single episode or recurrent, severe with psychotic symptoms (F32.3, F33.3 according to ICD-10)
- Severe mutism or stupor
- lifetime history of any psychotic or bipolar disorder
- severe neurological or internal concomitant diseases
- IQ \< 80; severe learning disability, brain damage or pervasive developmental disorder
- current alcohol or any illicit drug withdrawal syndrome according to DSM-5
- mental disorders secondary to a medical conditions or substance use disorders
- acute suicidality
- pregnancy and lactation period
- Missing eligibility for psychotherapy because of missing language skills
- Electroconvulsive therapy (ECT) in preparation
- Participation in further scientific studies
Key Trial Info
Start Date :
September 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03287362
Start Date
September 13 2017
End Date
December 31 2024
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Max Planck Institute of Psychiatry
Munich, Germany, 80804